top of page
  • Jonathan Poyer

September A Wild Month For Clinical Updates and Releases

The contrast between the green shoots in the biotech / pharma sector compared to the deteriorating broader economy became more apparent as Q3 drew to a close.

Upcoming Q3 earnings in a few weeks will be the next major data point to confirm the health of the sector.

September index performance:

  • Novo Nordisk (NOVO) acquired Forma Therapeutics (FMTX)

  • Merger of Sesen Bio (SESN) and Carisma Thera (private)

  • GSK PLC license agreement of Spero Thera oral antibiotic tebipenem

  • Myovant Sciences (MYOV) received a non-binding proposal to acquire Sumitomo Pharma for $2.5B

  • Astrazeneca (AZN) purchases Logic Thera for $70M

  • Amylyx Pharma had RELYVRIO drug approved by FDA in ALS treatment

  • Bristol Myers Squibb had oral TYK2 inhibitor treatment approved

  • Regeneron Pharma shared positive clinical data Eylea therapy for diabetic macular degeneration patients

  • Gilead Sciences posted strong results for disclosure of survival results for Trodelvy with breast cancer patients

  • Ideaya Biosciences reported positive data for Phase 2 trial in metastatic uveal melanoma

  • Akero Thera shared favorable update from 2B HARMONY trial

  • Eisai & Biogen announced positive results from late stage Alzheimer trial release

  • Rubius Thera announced a 75% headcount reduction, sale of their manufacturing facility and other cost saving measures

  • Horizon Thera announced a $500M share buyback

  • Johnson & Johnson announced a $5B share buyback program

11 views0 comments


bottom of page